HOXA9 and ovarian cancer: CDR1as also promotes the resistance of NSCLC to cisplatin through miR-641/Homeobox Protein Hox-A9 (HOXA9) pathway [87], while in ovarian cancer it shows the opposite effect through the miR-1270/Suppressor of Cancer Cell Invasion (SCAI) signal pathway [88].